Search results
We’re on the road with a new approach to clinical trials—one that expands access to cutting-edge medicines and treatments. Lilly is a medicine company turning science into healing to make life better for people around the world.
News about Eli Lilly, diabetes, obesity
News about Alzheimer's disease, FDA, donanemab
Also in the news
We’re a medicine company turning science into healing to make life better for people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges.
For more than 90 years, Lilly has been committed to diabetes and meeting the needs of people affected by diabetes with treatment options, support programs and more.
Jun 4, 2024 · The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
3 days ago · A panel of brain and Alzheimer’s experts convened by the U.S. Food and Drug Administration (FDA) voted unanimously on June 10 that a new Alzheimer’s drug developed by Eli Lilly, called ...
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
3 days ago · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early ...
4 days ago · Eli Lilly & Co.’s drug for Alzheimer’s has benefits that outweigh its risks, US drug regulatory advisers said, bringing the treatment’s long path to the market closer to a successful end.
4 days ago · A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly ’s Alzheimer’s drug donanemab, paving the way for the treatment to receive full approval in ...
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. Download PDF. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
